Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A vaccine approach to treating Parkinson’s disease

16.06.2005


Researchers at the University of California, San Diego (UCSD) School of Medicine working with scientists at Elan Pharmaceuticals, have reported promising results in mice of a vaccine approach to treating Parkinson’s and similar diseases. These results appear in the June edition of the journal Neuron.



Eliezer Masliah, M.D., Professor of Neurosciences and Pathology at UCSD, and colleagues at UCSD and Elan Pharmaceuticals in San Francisco, vaccinated mice using a a combination of the protein that abnormally accumulates in the brains of Parkinson’s (called human alpha-synuclein) and an adjuvant. This approach resulted in the generation of anti-alpha synuclein antibodies in mice that are specially bred by Masliah’s team to simulate Parkinson’s disease, resulting in reduced build-up of abnormal alpha-synuclein. The accumulation of abnormal alpha-synuclein is associated with degeneration of nerve cells and interference with normal inter-cellular communication, leading to Parkinson’s disease and dementia.

The work marks the first time a vaccine for this family of diseases has been found effective in animal studies. Scientists at Elan Pharmaceuticals have been working for the past few years in a vaccine for Alzheimer’s Disease.


The researchers focused on a spectrum of neurological disorders called Lewy body disease, which include Parkinson’s and Alzheimer’s. These disorders are marked by the presence of Lewy bodies -- abnormal clumps of alpha-synuclein -- in the brain. Normally, alpha-synuclein proteins support communications between brain cells, or neurons. However, when abnormal proteins clump together in the neurons, a build-up of synuclein can cut off neuron activity, blocking normal signaling between brain cells and ultimately choking the cells to death.

"We found that the antibodies produced by the vaccinated mice recognized and reduced only the abnormal form of alpha-synuclein, since the protein’s normal form is in a cellular compartment where antibodies can’t reach it," said Masliah. "Abnormal alpha-synuclein finds its way to the cell membrane, where antibodies can recognize it."

Masliah stressed that the team’s experimental active immunization, while effective in mice, may not be as useful in humans. "We would not want to actively immunize humans in this way by triggering antibody development, because one could create harmful inflammation," he cautioned. "However, it might be feasible to inject antibodies directly, as if the patient were creating his or her own."

The team, the first to identify the presence of these proteins in the human brain, originally thought the protein played an important role in the development of Alzheimer’s disease. Then, an explosion of research linked Lewy bodies and their constituent proteins to both Alzheimer’s and Parkinson’s. The team spent four years clarifying alpha-synuclein’s role in Parkinson’s, developing a mouse model that contained the faulty and normal genes for alpha-synuclein, and conducting the experiments that led to their current findings.

With evidence that this approach could be effective in treating Lewy Body disease, the UCSD researchers are now working with Elan Pharmaceuticals to develop alternative ways to produce alpha-synuclein antibodies, with the goal of making a vaccine that is safe and effective in humans. While this research could take many years and holds no promise of prevention or cure, the researchers are hopeful that the mouse studies are a step in the right direction.

"This shows the first demonstration of a vaccine for this family of disease," Masliah said.

Leslie Franz | EurekAlert!
Further information:
http://www.ucsd.edu

More articles from Health and Medicine:

nachricht Enabling technology in cell-based therapies: Scale-up, scale-out or program in-place
23.07.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht FAU researchers identify Parkinson's disease as a possible autoimmune disease
23.07.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Enabling technology in cell-based therapies: Scale-up, scale-out or program in-place

23.07.2018 | Health and Medicine

Abrupt cloud clearing events over southeast Atlantic Ocean are new piece in climate puzzle

23.07.2018 | Earth Sciences

The Maturation Pattern of the Hippocampus Drives Human Memory Deve

23.07.2018 | Science Education

VideoLinks
Science & Research
Overview of more VideoLinks >>>